Genelux (GNLX) Insider Mary Mirabelli Buys 31,566 Shares
Mary Mirabelli picked up 31,566 shares of Genelux Corporation in recent insider transactions.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mary Mirabelli bought 31,566 shares of Genelux Corporation ($GNLX) on June 16, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GNLX is down 3.6% after 1 week, down 6.9% after 1 month and down 20.1% to date (from the $3.03 close on Jun 16, 2026).
GNLX
Genelux Corporation
Key Points
- Mary Mirabelli acquired 31,566 shares of Genelux Corporation (NASDAQ: GNLX) on June 16, 2026.
- Genelux Corporation shares trade around $2.96, sitting between its 52-week low of $2.29 and high of $8.54.
- The clinical-stage biotech firm develops oncolytic viral immunotherapies for difficult-to-treat solid tumor types.
Get $GNLX trade alerts by text
We text you when insiders, Congress or big funds trade $GNLX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Genelux Corporation alert may contain errors. Disclosures
Mary Mirabelli Adds to Genelux Corporation Holdings
Mary Mirabelli acquired 31,566 shares of Genelux Corporation (NASDAQ: GNLX) on June 16, 2026. This transaction joins a series of similar share acquisitions filed by company insiders on the same date.
Genelux Corporation Stock and Market Position
Genelux shares recently traded at $2.96, moving close to its 50-day moving average of $2.72. The stock has traded between a 52-week low of $2.29 and a 52-week high of $8.54, with a market capitalization of roughly $115.8 million.
Recent Insider Activity at Genelux
Insiders including James Tyree and John Smither also acquired 31,566 shares each on June 16, 2026. These transactions reflect a wave of matching share acquisitions reported by multiple company insiders on the exact same date.
Inside Genelux Corporation's Biotechnology Pipeline
Genelux Corporation is a clinical-stage biopharmaceutical company focused on creating oncolytic viral immunotherapies for patients dealing with aggressive solid tumor types. Its lead product candidate, Olvi-Vec, targets ovarian cancer. The firm also maintains the CHOICE discovery platform and collaborates with Newsoara BioPharma Co. Ltd. to develop treatments in Greater China.
What to Watch Next for Genelux
Investors will likely keep an eye on upcoming regulatory updates, clinical trial progress for Olvi-Vec, and subsequent SEC filings from insiders. The company is not currently profitable, meaning standard P/E metrics do not apply as it continues funding its research pipeline.
Related Filing Alerts
Source: Mary Mirabelli's Form 4 filing on $GNLX (Jun 16, 2026). Find the original filing: GNLX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts